NCT03608696View on ClinicalTrials.gov

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

July 11, 2019

Study Completion Date

July 11, 2019

Conditions
Neonatal Abstinence SyndromeNeonatal Opiate Withdrawal Syndrome
Interventions
DRUG

Buprenorphine

buprenorphine 0.075 mg/ml solution

Trial Locations (1)

19107

Thomas Jefferson University Hosptial, Philadelphia

All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Thomas Jefferson University

OTHER

NCT03608696 - Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure | Biotech Hunter | Biotech Hunter